US Patent

US8623819 — Therapy for complications of diabetes

Method of Use · Assigned to AbbVie Deutschland GmbH and Co KG · Expires 2028-08-22 · 2y remaining

Vulnerability score 71/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using a selective endothelin A receptor antagonist to enhance glycemic control and/or insulin sensitivity in a human subject with diabetic nephropathy and/or metabolic syndrome.

USPTO Abstract

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET A ) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ET A receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ET A receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ET A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET A receptor antagonist.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3980 — atrasentan-hydrochloride

Patent Metadata

Patent number
US8623819
Jurisdiction
US
Classification
Method of Use
Expires
2028-08-22
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Deutschland GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.